Belaisch-Allart J, Allart J P, Dufêtre C, Briot P, Stalla-Bourdillon A
Department of Obstetrics and Gynaecology, Hospital A. Beclere, Clamart, France.
Hum Reprod. 1990 Jul;5(5):573-4. doi: 10.1093/oxfordjournals.humrep.a137146.
In earlier IVF programmes, subcutaneous buserelin (Suprefact, Hoechst) was initially administered three times per day (200 micrograms x 3); then twice daily (300 micrograms x 2). We now suggest that a single administration of 600 micrograms daily may be equally effective. In a preliminary study, 20 patients were selected on the basis of tubal or idiopathic infertility and received 0.6 ml buserelin subcutaneously once a day, beginning on day 1 or 2 of the cycle. A sufficient pituitary desensitization was obtained on day 10 in 75% of patients and on day 16 for 100% and the ongoing pregnancy rate was 35% per treatment cycle. A randomized study comparing the effect of 600 micrograms of buserelin administered in one (n = 50) or two injections (n = 46), has been carried out and indicates that the results in terms of the ovarian suppression and pregnancy rates, were similar. Therefore, this protocol represents a simplification of the treatment with buserelin.
在早期的体外受精（IVF）方案中，皮下注射布舍瑞林（Suprefact，赫斯特公司生产）最初是每天给药3次（200微克×3）；然后改为每天2次（300微克×2）。我们现在认为，每天单次给药600微克可能同样有效。在一项初步研究中，根据输卵管性或特发性不孕症选择了20例患者，从月经周期的第1天或第2天开始，每天皮下注射0.6毫升布舍瑞林。75%的患者在第10天获得了充分的垂体脱敏，100%的患者在第16天获得充分脱敏，每个治疗周期的持续妊娠率为35%。一项比较单次注射600微克布舍瑞林（n = 50）和两次注射（n = 46）效果的随机研究已经完成，结果表明，在卵巢抑制和妊娠率方面，两者结果相似。因此，该方案简化了布舍瑞林的治疗。
